Cost-of-illness studies in nine Central and Eastern European countries

Abstract

Background To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern European (CEE) region has not yet been published. Our main objective was to provide a general description about published COI studies from CEE. Methods A systematic search was performed between 1 January 2006 and 1 June 2017 in Medline, EMBASE, The Cochrane Library, CINAHL, and Web of Science to identify all relevant COI studies from nine CEE countries. COI studies reporting costs without any restrictions by age, co-morbidities, or treatment were included. Methodology, publication standards, and cost results were analysed. Results We identified 58 studies providing 83 country-specific COI results: Austria ( n = 9), Bulgaria ( n = 16), Croatia ( n = 3), the Czech Republic ( n = 10), Hungary ( n = 24), Poland ( n = 11), Romania ( n = 3), Slovakia ( n = 3), and Slovenia ( n = 4). Endocrine, nutritional, and metabolic diseases (18%), neoplasms (12%), infections (11%), and neurological disorders (11%) were the most frequently studied clinical areas, and multiple sclerosis was the most commonly studied disease. Overall, 57 (98%) of the studies explicitly stated the source of resource use data, 45 (78%) the study perspective, 34 (64%) the costing method, and 24 (58%) reported at least one unit costs. Regardless of methodological differences, a positive relationship was observed between costs of diseases and countries’ per capita GDP. Conclusions Cost-of-illness studies varied considerably in terms of methodology, publication practice, and clinical areas. Due to these heterogeneities, transferability of the COI results is limited across Central and Eastern European countries. Electronic supplementary material The online version of this article (10.1007/s10198-019-01066-x) contains supplementary material, which is available to authorized users.

Comparison of Cardiovascular Medicines Prices in Four European Countries

“…It could be used by manufacturers and regulatory bodies when determining a price variation between countries. It is also important for receiving information on CV medicine utilization and how it is affected by price variation, a problem for which there is relatively limited information in the country ( 48 ).…”

Availability and reimbursement of biological products for severe asthma in Bulgaria

“…18 This macro-costing approach possess some limitations because it focuses only on the pharmacotherapy cost and does not include any other costs, due to their unavailability in the country of such an information at central level. [19][20][21][22][23][24][25][26] The other limitation is the lack of data at patient level, as well number of packages sold for the whole period. This limits some of the calculations.…”

Az egészségügy finanszírozásának fenntarthatósága

“…A betegségek költségeiről (betegségteher), a direkt és az indirekt (munkából való kiesés), valamint az informális ellátás költségeiről néhány területen már rendelkezünk adatokkal, de ez az egészségpolitikai és finanszírozási döntésekhez még mindig nagyon kevés. Betegségteher-vizsgálatok hazánkban 24 (Kelet-Közép-Európában 54) esetben kerültek publikálásra (Brodszky et al, 2019). Az egészségnyereség mérésére az egészségügyben a QALY (Quality Adjusted Life Years, életminőséggel korrigált életév) használatos, egy 2016-os tanulmány azonban azt mutatja, hogy hazánkban összesen 47 olyan publikációval (Kelet-Közép-Európában összesen 147) rendelkezünk, amely különböző megbetegedések általános életminőségét (EQ-5D) vizsgálja (Rencz et al, 2016).…”